BACKGROUND: In pancreatitis, total pancreatectomy (TP) is an effective treatment for refractory pain. Islet cell auto-transplantation (IAT) may mitigate resulting endocrinopathy. Short-term morbidity data for TP + IAT and comparisons with TP are limited. METHODS: This study, using 2005-2011 National Surgical Quality Improvement Program data, examined patients with pancreatitis or benign neoplasms. Morbidity after TP alone was compared with that after TP + IAT. RESULTS: In 126 patients (40%) undergoing TP and 191 (60%) patients undergoing TP + IAT, the most common diagnosis was chronic pancreatitis. Benign neoplasms were present in 46 (14%) patients, six of whom underwent TP + IAT. Patients in the TP + IAT group were younger and had fewer comorbidities than those in the TP group. Despite this, major morbidity was more frequent after TP + IAT than after TP [n = 79 (41%) versus n = 36 (29%); P = 0.020]. Transfusions were more common after TP + IAT [n = 39 (20%) versus n = 9 (7%); P = 0.001], as was longer hospitalization (13 days versus 9 days; P < 0.0001). There was no difference in mortality. CONCLUSIONS: This study is the only comparative, multicentre study of TP and TP + IAT. The TP + IAT group experienced higher rates of major morbidity and transfusion, and longer hospitalizations. Better data on the longterm benefits of TP + IAT are needed. In the interim, this study should inform physicians and patients regarding the perioperative risks of TP + IAT.
BACKGROUND: In pancreatitis, total pancreatectomy (TP) is an effective treatment for refractory pain. Islet cell auto-transplantation (IAT) may mitigate resulting endocrinopathy. Short-term morbidity data for TP + IAT and comparisons with TP are limited. METHODS: This study, using 2005-2011 National Surgical Quality Improvement Program data, examined patients with pancreatitis or benign neoplasms. Morbidity after TP alone was compared with that after TP + IAT. RESULTS: In 126 patients (40%) undergoing TP and 191 (60%) patients undergoing TP + IAT, the most common diagnosis was chronic pancreatitis. Benign neoplasms were present in 46 (14%) patients, six of whom underwent TP + IAT. Patients in the TP + IAT group were younger and had fewer comorbidities than those in the TP group. Despite this, major morbidity was more frequent after TP + IAT than after TP [n = 79 (41%) versus n = 36 (29%); P = 0.020]. Transfusions were more common after TP + IAT [n = 39 (20%) versus n = 9 (7%); P = 0.001], as was longer hospitalization (13 days versus 9 days; P < 0.0001). There was no difference in mortality. CONCLUSIONS: This study is the only comparative, multicentre study of TP and TP + IAT. The TP + IAT group experienced higher rates of major morbidity and transfusion, and longer hospitalizations. Better data on the longterm benefits of TP + IAT are needed. In the interim, this study should inform physicians and patients regarding the perioperative risks of TP + IAT.
Authors: M'Balu A Webb; Severine C Illouz; Cristina A Pollard; Robert Gregory; John F Mayberry; Simon G Tordoff; Margaret Bone; Christine J Cordle; David P Berry; Michael L Nicholson; Patrick P Musto; Ashley R Dennison Journal: Pancreas Date: 2008-10 Impact factor: 3.327
Authors: David E R Sutherland; David M Radosevich; Melena D Bellin; Bernard J Hering; Gregory J Beilman; Ty B Dunn; Srinath Chinnakotla; Selwyn M Vickers; Barbara Bland; A N Balamurugan; Martin L Freeman; Timothy L Pruett Journal: J Am Coll Surg Date: 2012-03-06 Impact factor: 6.113
Authors: Melena D Bellin; Martin L Freeman; Sarah Jane Schwarzenberg; Ty B Dunn; Gregory J Beilman; Selwyn M Vickers; Srinath Chinnakotla; A N Balamurugan; Bernhard J Hering; David M Radosevich; Antoinette Moran; David E R Sutherland Journal: Clin Gastroenterol Hepatol Date: 2011-05-05 Impact factor: 11.382
Authors: R M Walsh; J R Aguilar Saavedra; G Lentz; A D Guerron; J Scheman; T Stevens; M Trucco; R Bottino; B Hatipoglu Journal: J Gastrointest Surg Date: 2012-06-07 Impact factor: 3.452
Authors: Horacio L Rodriguez Rilo; Syed A Ahmad; David D'Alessio; Yasuhiro Iwanaga; Joseph Kim; Kyuran A Choe; Jonathan S Moulton; Jill Martin; Linda J Pennington; Debbie A Soldano; Jamie Biliter; Steve P Martin; Charles D Ulrich; Lehel Somogyi; Jeffrey Welge; Jeffrey B Matthews; Andrew M Lowy Journal: J Gastrointest Surg Date: 2003-12 Impact factor: 3.267
Authors: Ahmad Hamad; Mazen S Zenati; Trang K Nguyen; Melissa E Hogg; Herbert J Zeh; Amer H Zureikat Journal: Surg Endosc Date: 2017-12-22 Impact factor: 4.584
Authors: Luis F Lara; Melena D Bellin; Emmanuel Ugbarugba; Jaimie D Nathan; Piotr Witkowski; Martin Wijkstrom; Jennifer L Steel; Kerrington D Smith; Vikesh K Singh; Sarah J Schwarzenberg; Timothy L Pruett; Bashoo Naziruddin; Leslie Long-Simpson; Varvara A Kirchner; Timothy B Gardner; Martin L Freeman; Ty B Dunn; Srinath Chinnakotla; Gregory J Beilman; David B Adams; Katherine A Morgan; Maisam A Abu-El-Haija; Syed Ahmad; Andrew M Posselt; Michael G Hughes; Darwin L Conwell Journal: Pancreas Date: 2019-10 Impact factor: 3.327
Authors: Joshua S Jolissaint; Linda W Langman; Claire L DeBolt; Jacob A Tatum; Allison N Martin; Andrew Y Wang; Daniel S Strand; Victor M Zaydfudim; Reid B Adams; Kenneth L Brayman Journal: Clin Transplant Date: 2016-10-17 Impact factor: 2.863
Authors: Amer H Zureikat; Trang Nguyen; Brian A Boone; Martin Wijkstrom; Melissa E Hogg; Abhinav Humar; Herbert Zeh Journal: Surg Endosc Date: 2014-07-09 Impact factor: 4.584
Authors: Michael Quartuccio; Erica Hall; Vikesh Singh; Martin A Makary; Kenzo Hirose; Niraj Desai; Christi Walsh; Daniel Warren; Zhaoli Sun; Ellen Stein; Rita R Kalyani Journal: J Clin Endocrinol Metab Date: 2017-03-01 Impact factor: 5.958